Induction of antitumor immunity by CCR2 transduced CD8+TILs in mouse lung carcinoma

Yi Wan,Tianyu Fan,Xin Wang,Bin Wang,Bei Zhang,Li Zhang
DOI: https://doi.org/10.21203/rs.3.rs-2524942/v1
2023-01-01
Abstract:Abstract Despite recent therapeutic progress in lung carcinoma, the overall survival still remains poor. Therefore, exploration of novel therapeutic strategies remains a potential objective. Chemokine was first discovered as chemotactic factor during inflammation. The CCL2-CCR2 axis is one of the major chemokine signaling pathways, and has multiple functions in tumor microenvironment, such as tumor cell proliferation and invasiveness, angiogenesis, and recruitment of immune cells. In our previous study, CCR2 was found with the distinct expression modes from other cancer types such as breast cancer, pancreatic ductal adenocarcinoma, or prostate cancer: The expression was positive correlation with the prognosis and negative correlation with T and N classifications of lung carcinoma, and was higher in antitumor immune cells of CD8 + TILs, M1 macrophages, and active/resting CD4 + T memory cells compared other tumor-promoting immune cells. In the present study, we verified CCR2 expression in human and mouse lung carcinoma, and the antitumor functions were studied in mouse lung carcinoma isolated CD8 + TILs. We found that retroviral CCR2 transduction led to the activation in CD8 + TILs, improvement of its migration to the tumor microenvironment, promotion of the early apoptosis of tumor cells, and inhibition of the proliferation of tumor cells. All the data implied the antitumor function of CD8 + TILs with up-regulated CCR2 in lung carcinoma may be provide novel targeting therapeutic strategy in the near future.
What problem does this paper attempt to address?